
Commentary: Drug Survival Associated with Effectiveness and Safety of Treatment with Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients with Psoriasis
Real-world evidence studies become crucial to achieving the evidence needed in clinical practice. But how are data evaluated in the complexity of the real world? Alexander Egeberg, MD, PhD, DMSc, discusses a present study that examined drug survival among 16,122 treatment courses of biologic therapy with either guselkumab, ixekizumab, secukinumab, ustekinumab, or adalimumab, using United Kingdom registry data.